Patient demand for compounded GLP-1 agonists for obesity may have reached a point that will be difficult to reverse, even if the US Food and Drug Administration removes semaglutide from the drug shortage list and compounding pharmacies are barred from making the products.
Compounded GLP-1s For Obesity: Is The Genie Out Of The Bottle?
Patient demand for compounded versions of FDA-approved obesity drugs is unlikely to dissipate, even if semaglutide’s “shortage” status is resolved. The issue likely will continue to be a high-profile concern for the brand industry.
